亚盛医药-B 将在 2023 年美国血液学会年会（ASH）展示奥雷巴替尼及 APG-2575 的多项临床进展。

Intelligence Finance APP News: Yasheng Medicine-B announced that Osimertinib (trade name: Tagrisso®) and APG-2575 (Lisaftoclax) have made multiple clinical advancements and have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, with 2 of them being oral presentations. This marks the 6th consecutive year that Osimertinib has been selected for an oral presentation at the ASH Annual Meeting, demonstrating the international hematology community's recognition of its efficacy and safety. Osimertinib (trade name: Tagrisso®) has broad potential in the treatment of various solid tumors and hematologic malignancies. Yasheng Medicine will present the latest progress of a randomized controlled registration phase II study on the treatment of chronic myeloid leukemia in chronic phase (CML-CP) patients resistant to first- and second-generation tyrosine kinase inhibitors (TKIs). The study data showed that compared to the control group receiving the best available therapy (BAT), the Osimertinib (trade name: Tagrisso®) treatment group demonstrated statistically and clinically significant improvement in event-free survival (EFS) in TKI-resistant/intolerant CML-CP patients, achieving the primary endpoint of this study. Another oral presentation will be given by Professor Gong Xiaoyuan from the Hematology Hospital of the Chinese Academy of Medical Sciences, who will present the early results of a phase II clinical trial on the treatment of newly diagnosed Ph+ ALL patients with Tagrisso in combination with Venetoclax and low-intensity chemotherapy.